We are live on ! Find out more
XENE icon

Xenon Pharmaceuticals

211 hedge funds and large institutions have $2.99B invested in Xenon Pharmaceuticals in 2024 Q4 according to their latest regulatory filings, with 29 funds opening new positions, 66 increasing their positions, 69 reducing their positions, and 22 closing their positions.

New
Increased
Maintained
Reduced
Closed

5,216% more call options, than puts

Call options by funds: $4.36M | Put options by funds: $82K

44% more funds holding in top 10

Funds holding in top 10: 9 → 13 (+4)

32% more first-time investments, than exits

New positions opened: 29 | Existing positions closed: 22

31% more capital inflows, than outflows

Capital inflows: $261M | Capital outflows: $200M

2% more funds holding

Funds holding: 206 → 211 (+5)

1.23% more ownership

Funds ownership: 98.85% → 100.08% (+1.2%)

4% less repeat investments, than reductions

Existing positions increased: 66 | Existing positions reduced: 69

Holders
211
Holders Change
+5
Holders Change %
+2.43%
% of All Funds
2.77%
Holding in Top 10
13
Holding in Top 10 Change
+4
Holding in Top 10 Change %
+44.44%
% of All Funds
0.17%
New
29
Increased
66
Reduced
69
Closed
22
Calls
$4.36​M
Puts
$82​K
Net Calls
+$4.28​M
Net Calls Change
+$636​K

XENE Hedge Fund Activity: Q4 2024 in Review

211 of the 7,628 institutional investors tracked by Wall St. Rank reported a position in Xenon Pharmaceuticals (XENE) for Q4 2024, worth a combined $2.99B — up 1.4% from $2.95B a quarter earlier.

Buyers outnumbered sellers: 29 funds opened new XENE positions and 22 closed out — a net gain of 7 holders — while 66 added to existing stakes and 69 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $25.1M. The largest seller was Citadel Advisors, cutting an estimated $16.3M.

  • 211 institutional investors held Xenon Pharmaceuticals (XENE) as of Q4 2024, up from 206 in Q3 2024.
  • Funds reported $2.99B of Xenon Pharmaceuticals stock for Q4 2024, up 1.4% quarter-over-quarter.
  • 29 funds opened new Xenon Pharmaceuticals positions in Q4 2024 and 22 closed out, a net change of +7 holders.
  • The largest Xenon Pharmaceuticals buyer in Q4 2024 was Fidelity Investments, an estimated $25.1M added.
  • The largest Xenon Pharmaceuticals seller in Q4 2024 was Citadel Advisors, an estimated $16.3M sold.

Based on aggregated 13F filings for Q4 2024.